MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
Phase 2
Completed
- Conditions
- Chronic Renal InsufficiencySerum Creatinine ConcentrationContrast Media Exposition
- Registration Number
- NCT00223548
- Lead Sponsor
- University of Ulm
- Brief Summary
The purpose of this study is to determine wether Mesna could prevent contrast-induced nephropathy
- Detailed Description
Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.
The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
- stable chronic renal insufficiency
- serum creatinine concentration > 1,5 mg/dl
Exclusion Criteria
- Dialyzed patients
- patients with acute renal failure
- received iodinated contrast media within 7 days before study entry
- known allery to Mesna, pregnancy, and administration of dopamine, mannitol or N-acetylcysteine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Contrast-agent associated nephrotoxicity was defined as an increase in serum creatinine concentration >0.5 mg/dl (44 umol/l) of the baseline value 48 h after administration of the contrast media.
- Secondary Outcome Measures
Name Time Method Need for dialysis after the administration of contrast media.
Trial Locations
- Locations (1)
Division of Nephrology, University of Ulm
🇩🇪Ulm, Germany